首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1897784

疫苗佐劑市場規模、佔有率和成長分析（按產品、佐劑類型、給藥途徑、疾病類型、應用、疫苗類型和地區分類）－2026-2033年產業預測

Vaccine Adjuvants Market Size, Share, and Growth Analysis, By Product (Emulsion Adjuvants, Pathogen Components), By Adjuvant Type, By Route Of Administration, By Disease Type, By Application, By Vaccine Type, By Region - Industry Forecast 2026-2033

出版日期: 2025年12月26日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全球疫苗佐劑市場規模將達到 7.1171 億美元，從 2025 年的 7.5591 億美元成長到 2033 年的 12.2403 億美元，在預測期（2026-2033 年）內，複合年成長率為 6.21%。

由於新發和再發病原體引發的感染疾病日益猖獗，全球疫苗佐劑市場正經歷顯著成長。感染疾病的激增凸顯了疫苗接種的重要性，進而導致對增強免疫效力的佐劑的需求不斷成長。佐劑是建構強大感染疾病防禦機制的關鍵要素，它透過延長注射部位抗原的持續時間和調節免疫反應來增強疫苗效力。近期健康危機引發的全球醫療保健轉型進一步凸顯了疫苗接種策略的價值。此外，研發領域的持續進步催生了許多創新疫苗候選產品，為佐劑（疫苗效力最大化的關鍵成分）拓展了市場機會。

全球疫苗佐劑市場促進因素

受新冠肺炎疫情的嚴重影響，全球健康問題日益嚴峻，導致疫苗需求激增，尤其是使用佐劑的疫苗。這種對疫苗接種策略的日益重視旨在有效對抗各種感染疾病和新出現的病原體，並維持群體免疫。為此，疫苗生產產業正積極尋求創新解決方案，透過投資先進的佐劑技術來提高疫苗效力。這項持續的努力不僅應對了當前的健康挑戰，也加強了公共衛生防禦，抵禦未來的威脅，從而推動了全球疫苗佐劑市場的成長。

限制全球疫苗佐劑市場的因素

全球疫苗佐劑市場面臨許多限制因素，其中最主要的限制因素是嚴格的監管壁壘，這些壁壘限制了產品的上市核准流程。這些嚴格的要求可能會延緩新佐劑的上市，最終影響其市場進入時間。此外，日益嚴格的監管環境推高了生產成本，增加了企業的財務負擔，可能阻礙市場成長。遵守複雜的法規結構需要投入大量資源，這對尋求開發和推出新產品的中小企業尤其具有挑戰性。在競爭激烈的市場環境中，確保符合安全法規也帶來了額外的挑戰。

全球疫苗佐劑市場趨勢

全球疫苗佐劑市場正呈現出對個人化疫苗接種方案顯著發展的趨勢，該方案著重於根據每位患者獨特的基因和免疫特徵量身定做疫苗。這種創新方法旨在透過使用針對特定免疫需求的客製化佐劑來提高疫苗效力和改善患者預後。從「一刀切」模式轉向更具針對性的策略轉變，有望推動市場取得重大進展，並刺激對先進佐劑技術的需求。這一發展不僅有望提高疫苗接種的整體有效性，還有助於提高患者在接種過程中的參與和依從性。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

GSK plc（UK）
SEPPIC（France）
Croda International Plc（UK）
SPI Pharma（USA）
Agenus Inc.（USA）
Phibro Animal Health Corporation（USA）
Aurorium（USA）
Dynavax Technologies Corporation（USA）
Novavax Inc.（USA）
Merck KGaA（Germany）
Vaxine Pty Ltd.（Australia）
Hawaii Biotech Inc.（USA）
CSL Limited（Australia）
OZ Biosciences（France）
InvivoGen（USA）
Allergy Therapeutics（UK）
EuBiologics Co., Ltd.（South Korea）
Pacific GeneTech Limited（USA）
Riboxx GmbH（Germany）
Oncovir, Inc.（USA）

結論與建議

簡介目錄

Product Code: SQMIG35I2155

Global Vaccine Adjuvants Market size was valued at USD 711.71 Million in 2024 and is poised to grow from USD 755.91 Million in 2025 to USD 1224.03 Million by 2033, growing at a CAGR of 6.21% during the forecast period (2026-2033).

The global vaccine adjuvants market is experiencing significant growth driven by the rising prevalence of infectious diseases caused by both emerging and re-emerging pathogens. This surge in infectious diseases heightens the importance of vaccinations, leading to a greater demand for adjuvants that enhance immunization effectiveness. As a critical factor in developing robust defenses against infections, adjuvants boost vaccine potency by prolonging antigen presence at injection sites and modulating immune responses. The global shift towards preventive healthcare, influenced by recent health crises, further emphasizes the value of vaccination strategies. Additionally, ongoing advancements in research and development are yielding a broader array of innovative vaccine candidates, thereby expanding the market opportunities for adjuvants, which are essential for maximizing vaccine efficacy.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Vaccine Adjuvants market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Vaccine Adjuvants Market Segments Analysis

Global Vaccine Adjuvants Market is segmented by Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type and region. Based on Product, the market is segmented into Emulsion Adjuvants, Pathogen Components, Saponin-Based Adjuvants, Particulate-Based Adjuvants and Other Adjuvants. Based on Adjuvant Type, the market is segmented into Organic Adjuvants and Inorganic Adjuvants. Based on Route Of Administration, the market is segmented into Intramuscular, Subcutaneous and Other Routes of Administration. Based on Disease Type, the market is segmented into Infectious Diseases, Cancer and Other Diseases. Based on Application, the market is segmented into Research Applications and Commercial Applications. Based on Vaccine Type, the market is segmented into Human Vaccines, Veterinary Vaccines and Other Animals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Vaccine Adjuvants Market

The surge in global health concerns, significantly influenced by the COVID-19 pandemic, has led to an intensified demand for vaccinations, particularly those utilizing adjuvants. This heightened focus on immunization strategies aims to effectively combat diverse infectious diseases and emerging pathogens, thereby ensuring community immunity is maintained. In response, the vaccine manufacturing sector is actively pursuing innovative solutions to enhance the efficacy of vaccines by investing in advanced adjuvant technologies. This ongoing pursuit not only addresses immediate health challenges but also fortifies public health defenses against future threats, driving the growth of the global vaccine adjuvants market.

Restraints in the Global Vaccine Adjuvants Market

The global Vaccine Adjuvants market faces significant constraints due to stringent regulatory barriers that govern the licensing process. These rigorous requirements can lead to delays in the introduction of new adjuvants, ultimately impacting the timeline for market entry. Furthermore, the heightened regulatory landscape can increase manufacturing costs, creating additional financial burdens that may stifle market growth. Navigating the complex regulatory framework demands considerable resources, posing challenges for companies, particularly smaller businesses, that aspire to innovate and introduce new products. Ensuring compliance with safety regulations adds another layer of difficulty in an already competitive market environment.

Market Trends of the Global Vaccine Adjuvants Market

The Global Vaccine Adjuvants market is experiencing a notable trend towards personalized immunization plans, where the focus is on tailoring vaccines to the unique genetic and immune profiles of individual patients. This innovative approach aims to enhance vaccine efficacy and patient outcomes by utilizing custom-designed adjuvants that cater to specific immunological needs. By shifting from a one-size-fits-all model to more targeted strategies, the market is poised for significant advancements, driving demand for sophisticated adjuvant technologies. This evolution not only promises to improve the overall effectiveness of vaccinations but also enhances patient engagement and compliance in the immunization process.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Regulatory Analysis
Patent Analysis

Global Vaccine Adjuvants Market Size by Product & CAGR (2026-2033)

Market Overview
Emulsion Adjuvants
Saponin-Based Adjuvants
Particulate-Based Adjuvants
Other Adjuvants

Global Vaccine Adjuvants Market Size by Adjuvant Type & CAGR (2026-2033)

Market Overview
Organic Adjuvants
Inorganic Adjuvants
Global Vaccine Adjuvants Market Size by Route Of Administration & CAGR (2026-2033)
Market Overview
Intramuscular
Subcutaneous
Other Routes of Administration

Global Vaccine Adjuvants Market Size by Disease Type & CAGR (2026-2033)

Market Overview
Infectious Diseases
Cancer
Other Diseases

Global Vaccine Adjuvants Market Size by Application & CAGR (2026-2033)

Market Overview
Research Applications
Commercial Applications

Global Vaccine Adjuvants Market Size by Vaccine Type & CAGR (2026-2033)

Market Overview
Human Vaccines
- Infectious Diseases
- Therapeutic
Veterinary Vaccines
- Companion Animals
- Livestock Animals
Other Animals

Global Vaccine Adjuvants Market Size & CAGR (2026-2033)

North America (Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type)
- US
- Canada
Europe (Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type)
- Brazil
- Rest of Latin America
Middle East & Africa (Product, Adjuvant Type, Route Of Administration, Disease Type, Application, Vaccine Type)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

GSK plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SEPPIC (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Croda International Plc (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
SPI Pharma (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Agenus Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Phibro Animal Health Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Aurorium (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Dynavax Technologies Corporation (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novavax Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck KGaA (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Vaxine Pty Ltd. (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hawaii Biotech Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CSL Limited (Australia)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
OZ Biosciences (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
InvivoGen (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Allergy Therapeutics (UK)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
EuBiologics Co., Ltd. (South Korea)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pacific GeneTech Limited (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Riboxx GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Oncovir, Inc. (USA)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments